| Document |
Document Title |
|
JP2012193183A |
To develop novel analogues of F152.The present invention relates to: compounds having the following formula (I); methods for synthesizing them; and methods for the use thereof in the treatment of various disorders including inflammatory ...
|
|
JP2012523382A |
This invention is directed generally to a process for producing Zeranol that eliminates high pressure and high temperature hydrogenations and provides high selectivity for Zeranol at improved yields.
|
|
JP5028594B2 |
It is intended to provide a compound which is useful in preventing and treating arteriosclerosis-related diseases because of binding to a receptor as a ligand specific to human liver X receptor alpha (LXRalpha), i.e., a nuclear receptor,...
|
|
JP5026639B2 |
This invention relates to a composition comprising antimony trifluoride and silica, a method for the preparation of said composition and the use of said composition as catalyst. Examples of the silica are hexagonal mesoporous silica (HMS...
|
|
JP5015111B2 |
The compounds of the present invention are prepared directly or indirectly by modifying the compounds that are naturally produced from Saccharopolyspora spinosa. The compounds of the invention have been shown to have activity against ins...
|
|
JP4974415B2 |
The present invention relates to novel aryl-substituted S(O)m cycles of the formula (I):in whichF<1>, F<2>, G, V, W, X, Y, Z and m are each as defined in the description, to processes for their preparation and to their use in agriculture...
|
|
JP4953521B2 |
|
|
JP2012511027A |
The invention provides compositions or pharmaceutical compositions of novel high penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capabl...
|
|
JP4934025B2 |
The invention relates to a process for preparing saturated or unsaturated lactones. This process involves reacting a bicyclic compound or a monocyclic compound with hydrogen peroxide in the presence of a first acid having a pKa of 3 or l...
|
|
JP4928937B2 |
The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metas...
|
|
JP4912557B2 |
A process of the present invention produces an organic compound by allowing a compound containing an electron attractive group of following Formula (1): wherein Y is an electron attractive group; and R and R are each a hydrogen atom or a...
|
|
JP4903333B2 |
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: ...
|
|
JP4889920B2 |
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: ...
|
|
JP4885067B2 |
The present invention relates to compounds of the formulaQ is selected from the group consisting ofG is selected from the group consisting of alkyl, substituted alkyl, substituted or unsubstituted aryl, heterocyclo,W is O or NR15;X is O ...
|
|
JP4884230B2 |
Disclosed are ´-amino-³-hydroxy-É-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of ad...
|
|
JP4862655B2 |
The compounds in the present invention, for example, the compound represented by the formula: has an excellent therapeutic and prophylactic effects against inflammatory bowel disease. Further, they are excellent in absorption and in vivo...
|
|
JP4856376B2 |
The present invention relates to novel metastable derivatives of benzoxepines of the formula (I) in which n represents 0, 1 or 2; and the radicals R, which may be identical or different, are alkyl or alkoxy groups, or halogen atoms, whic...
|
|
JP4856826B2 |
A vinyl ether compound represent by following Formula (4): wherein ring Z is any one of cyclic groups represented by following Formulae (5) through (12): wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , and X 8 are each a substituent co...
|
|
JP4853934B2 |
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by t...
|
|
JP4852100B2 |
The invention relates to the use of a compound of the formula (I) or a pharmaceutically acceptable addition salt thereof for the preparation of a medicament for the prophylaxis and/or treatment of muscular dystrophy.
|
|
JP4841837B2 |
The present invention refers to a microporous crystalline material of zeolitic nature (ITQ-22) which, in the calcined state, has the empirical formula wherein M is H+ or at least one inorganic cation of charge +n; X is at least one chemi...
|
|
JP2011225549A |
To provide an industrially advantageous method for producing a lactone compound and a hydroxycarboxylic acid compound from a cyclic ketone compound.There is provided a method for producing the lactone compound and the hydroxycarboxylic a...
|
|
JP2011219363A |
To provide a polymer exhibiting excellent roughness reduction capability, solubility, compatibility, defect reduction capability, exposure sensitivity and the like when used as a positive photoresist, a monomer for producing the same, an...
|
|
JP4807903B2 |
The present invention provides vacuolar-type (H+)-ATPase-inhibiting compounds, compositions thereof, and methods of using them to treat or prevent a condition treatable by the inhibition of a vacuolar-type (H+)-ATPase. The composition of...
|
|
JP4805552B2 |
To provide a new condensed ring compound having the activity of regulating GPR40 receptor function and being useful as an insulin secretion promoter or as a preventive/therapeutic agent for diabetes mellitus, etc. The present invention p...
|
|
JP2011215617A |
To provide a composition and a method for reducing pattern collapse.A radiation-sensitive composition and a method for using the composition to reduce the probability of pattern collapse are provided. The radiation-sensitive composition ...
|
|
JP4800927B2 |
The present invention relates to a process for the oxidation, in an inert solvent, of a non-aromatic or non-enonic ethylenic bond or of a non-conjugated cyclic ketones into the corresponding epoxides, respectively lactone, using H2O2 as ...
|
|
JP4796300B2 |
Motilide compounds having the formula (I), wherein R1, R2, R3, and R4 are as defined herein, and methods for their preparation and use in the treatment of diseases or conditions characterized by impaired gastric motility.
|
|
JP2011201777A |
To provide a compound regulating the function of TRPV1 receptor, and to provide an agent for preventing or treating disease associated with the TRPV1 receptor, containing the derivative as an active ingredient.There are provided the comp...
|
|
JP2011201778A |
To provide a compound that modulates the function of TRPV1 receptor, a TRPV1 receptor modulator comprising the derivative as an active ingredient, and an agent for preventing or treating a disease involving TRPV1 receptor, such as pain.T...
|
|
JP4772780B2 |
The present invention relates to the compounds of general formula (I) : wherein R, R1, R2 are as defined in claim 1.Compounds of formula (I) are particularly useful for preparing 3,3-dimethyl-5-formyl-2,3-dihydrobenzoxepines derivatives.
|
|
JP4754566B2 |
A compound represented by formula (I'): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R 1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN...
|
|
JP4751823B2 |
Among the compounds represented by the general formula (1), (in the formula, n is an integer of 7 to 13) in particular, 11-methyl-13-tridecanolide of which n=8, 12-methyl-14-tetradecanolide of which n=9, and 13-methyl-15-pentadecanolide ...
|
|
JP4741776B2 |
Applicants have developed a process for the oxidation of ketones to esters. The process involves contacting the ketone with hydrogen peroxide and a catalyst at oxidation conditions. The catalyst is a molecular sieve represented by the em...
|
|
JP2011144153A |
To provide a method for easily and inexpensively synthesizing a macrocyclic lactone by which the length of the carbon chain can be regulated freely.The method for synthesizing the macrocyclic lactone which is represented by formula (II) ...
|
|
JP2011519860A |
The present invention provides for a non-naturally occurring polyketide synthase (PKS) capable of synthesizing a carboxylic acid or a lactone, and a composition such that a carboxylic acid or lactone is included. The carboxylic acid or l...
|
|
JP2011132259A |
To provide a topically administrable, multi-dose anti-allergy composition suitable for use by patients wearing contact lenses, wherein the composition comprising: an anti-allergy effective amount of a drug selected from the group consist...
|
|
JP4719671B2 |
The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metas...
|
|
JP4717163B2 |
The compounds of the present invention are prepared directly or indirectly by modifying the compounds that are naturally produced from Saccharopolyspora spinosa. The compounds of the invention have been shown to have activity against ins...
|
|
JP4700867B2 |
|
|
JP4698823B2 |
|
|
JP2011105762A |
To provide a method for preparing 1-hydroperoxy-16-oxabicyclo[10.4.0]hexadecane (DDP-OOH).The method for preparing 1-hydroperoxy-16-oxabicyclo[10.4.0]hexadecane (DDP-OOH) includes reacting 13-oxabicyclo[10.4.0]hexadec-1(12)-ene (DDP) wit...
|
|
JP2011105694A |
To provide a peroral solid composition which is stabilized and prevents simply the discoloration and decomposition of olopatadine or a pharmaceutically acceptable salt thereof owing to a light or the like.The peroral solid composition in...
|
|
JP2011105766A |
To provide pharmaceutical compositions and a method for treating mammary tumor metastasis in a subject.The invention provides pharmaceutical compositions comprising a therapeutically effective amount of compounds of general formula (I), ...
|
|
JP2011516434T |
The specific many forms exceeding 95% of purity of ペンタ mycin and ペンタ mycin, solvent 和物, those refining processes, and the method of decreasing the speed of decomposition of ペンタ mycin are indicated.
|
|
JP4681732B2 |
The invention relates to epothilone analog represented by the formula I wherein (i) R 2 is absent or oxygen; "a" can be either a single or double bond; "b" can be either absent or a single bond; and "c" can be either absent or a single b...
|
|
JP2011513248A |
The present invention discloses novel Epothilone analogues, their pharmaceutical compositions, their use and their preparations, especially discloses the compounds of general formula I, their preparations and their use for preparing ther...
|
|
JP2011510017A |
Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising...
|
|
JP4659251B2 |
To provide a method effectively and industrially advantageously producing a hydroxy-4-oxatricyclo[4.3.1.1<3> ,<8> ]undecan-5-one and its methacrylate in a high yield. This method of production for hydroxy-4- oxatricyclo[4.3.1.1<3> ,<8> ]...
|
|
JP4662635B2 |
Recombinant nucleic acids that encode all or a portion of the epothilone polyketide synthase (PKS) are used to express recombinant PKS genes in host cells for the production of epothilones, epothilone derivatives, and polyketides that ar...
|
